Mark Linch

4.1k total citations
74 papers, 1.9k citations indexed

About

Mark Linch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mark Linch has authored 74 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 22 papers in Molecular Biology. Recurrent topics in Mark Linch's work include Cancer Immunotherapy and Biomarkers (27 papers), Prostate Cancer Treatment and Research (19 papers) and Bladder and Urothelial Cancer Treatments (14 papers). Mark Linch is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Prostate Cancer Treatment and Research (19 papers) and Bladder and Urothelial Cancer Treatments (14 papers). Mark Linch collaborates with scholars based in United Kingdom, United States and France. Mark Linch's co-authors include Peter J. Parker, Carine Rossé, Angus J.M. Cameron, Katrina Boeckeler, Stéphanie Kermorgant, Charlotte Benson, Aisha Miah, Ian Judson, Thomas Powles and Khin Thway and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark Linch

72 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Linch United Kingdom 23 887 690 492 363 236 74 1.9k
Ralph Fritsch Germany 23 903 1.0× 678 1.0× 292 0.6× 285 0.8× 142 0.6× 67 1.8k
Ann Marie Egloff United States 29 1.2k 1.4× 837 1.2× 430 0.9× 320 0.9× 104 0.4× 63 2.3k
Marianna Kruithof‐de Julio Switzerland 25 1.2k 1.3× 651 0.9× 647 1.3× 343 0.9× 196 0.8× 76 2.2k
Cu Nguyen United States 15 2.0k 2.2× 541 0.8× 379 0.8× 253 0.7× 165 0.7× 24 2.5k
Juan A. Recio Spain 23 1.0k 1.1× 526 0.8× 296 0.6× 111 0.3× 253 1.1× 53 1.8k
Michiya Nishino United States 18 888 1.0× 720 1.0× 327 0.7× 374 1.0× 187 0.8× 63 2.0k
Douglas W. Strand United States 27 1.0k 1.1× 529 0.8× 835 1.7× 192 0.5× 159 0.7× 73 2.4k
Òscar M. Tirado Spain 28 952 1.1× 435 0.6× 533 1.1× 109 0.3× 262 1.1× 57 1.8k
Takanori Goi Japan 26 1.2k 1.4× 712 1.0× 207 0.4× 333 0.9× 439 1.9× 149 2.1k

Countries citing papers authored by Mark Linch

Since Specialization
Citations

This map shows the geographic impact of Mark Linch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Linch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Linch more than expected).

Fields of papers citing papers by Mark Linch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Linch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Linch. The network helps show where Mark Linch may publish in the future.

Co-authorship network of co-authors of Mark Linch

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Linch. A scholar is included among the top collaborators of Mark Linch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Linch. Mark Linch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Linch, Mark, Gianmarco Leone, Yien Ning Sophia Wong, et al.. (2024). Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 5013–5013. 5 indexed citations
2.
Jones, Robert J., Simon J. Crabb, Mark Linch, et al.. (2024). Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer. 130(6). 897–907. 12 indexed citations
3.
4.
Rodríguez‐Vida, Alejo, Syed A. Hussain, Carlos Álvarez-Fernández, et al.. (2023). 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2). Annals of Oncology. 34. S1201–S1202. 4 indexed citations
5.
Hussain, Syed A., J.F. Lester, Richard A. Jackson, et al.. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 20 indexed citations
6.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2021). Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology. 4(3). 456–463. 19 indexed citations
7.
Parker, Peter J., Véronique Calleja, Probir Chakravarty, et al.. (2020). Equivocal, explicit and emergent actions of PKC isoforms in cancer. Nature reviews. Cancer. 21(1). 51–63. 41 indexed citations
8.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2020). 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Annals of Oncology. 31. S1319–S1319. 3 indexed citations
9.
Ng, Kenrick, Ursula McGovern, Myria Galazi, et al.. (2020). Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis. Prostate Cancer and Prostatic Diseases. 24(1). 166–168. 1 indexed citations
10.
Hull, James H., et al.. (2020). Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?. European Urology. 78(1). 9–10. 4 indexed citations
11.
Angelis, Aris, Mark Linch, Gilberto Montibeller, et al.. (2019). Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. Social Science & Medicine. 246. 112595–112595. 28 indexed citations
12.
Martín-Liberal, Juan, Angus J.M. Cameron, Jeroen Claus, et al.. (2014). Targeting protein kinase C in sarcoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846(2). 547–559. 8 indexed citations
13.
Linch, Mark, Spyridon Gennatas, R. Gunapala, et al.. (2014). A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer. 14(1). 674–674. 26 indexed citations
14.
Linch, Mark, Aisha Miah, Khin Thway, Ian Judson, & Charlotte Benson. (2014). Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies. Nature Reviews Clinical Oncology. 11(4). 187–202. 169 indexed citations
15.
Gough, Nicholas, Aisha Miah, & Mark Linch. (2014). Nonsurgical oncological management of cancer pain. Current Opinion in Supportive and Palliative Care. 8(2). 102–111. 12 indexed citations
16.
17.
Martín-Liberal, Juan, Salma Alam, Anastasia Constantinidou, et al.. (2013). Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. Sarcoma. 2013. 1–6. 50 indexed citations
18.
Parker, Peter J., Verline Justilien, Philippe Riou, Mark Linch, & Alan P. Fields. (2013). Atypical Protein Kinase Cι as a human oncogene and therapeutic target. Biochemical Pharmacology. 88(1). 1–11. 76 indexed citations
19.
Rossé, Carine, Katrina Boeckeler, Mark Linch, et al.. (2012). Binding of Dynein Intermediate Chain 2 to Paxillin controls Focal adhesion dynamics and migration.. Journal of Cell Science. 125(Pt 16). 3733–8. 17 indexed citations
20.
Linch, Mark, et al.. (2007). Renal tubular acidosis due to oxaliplatin. Annals of Oncology. 18(4). 805–806. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph Fritsch Breakdown of academic impact, for papers by Ann Marie Egloff Breakdown of academic impact, for papers by Marianna Kruithof‐de Julio Breakdown of academic impact, for papers by Cu Nguyen Breakdown of academic impact, for papers by Juan A. Recio Breakdown of academic impact, for papers by Michiya Nishino Breakdown of academic impact, for papers by Douglas W. Strand Breakdown of academic impact, for papers by Òscar M. Tirado Breakdown of academic impact, for papers by Takanori Goi
Rankless by CCL
2026